Researchers in the Journal of Molecular Medicine questioned the scientific performance of the FDA-cleared Lumipulse G plasma ratio for Alzheimer’s disease screening. The review argues the p-tau217/Aβ1–42 metric shows flaws, sharpening scrutiny on how the blood test stratifies patients and how results should be interpreted in clinical pathways.